Food Allergy Research and Resource Program, Department of Food Science and Technology, University of Nebraska, Lincoln, NE 68583-0955, USA.
Expert Rev Clin Immunol. 2005 Nov;1(4):561-78. doi: 10.1586/1744666X.1.4.561.
Genetically modified plants are created by the insertion of foreign genes into plant cells followed by the generation of reproductively stable stock plants for rapid and precise improvements in agricultural crops. Current products provide resistance to insect pests, plant viruses or herbicides. Future products include nutritionally enhanced crops, salt and draught tolerant crops and plant produced industrial enzymes or pharmaceuticals. The risk that a newly expressed protein might cause serious allergic reactions is real, but the probability is relatively small. Regulatory agencies require a premarket evaluation of the genetically modified crop to reduce the potential for increased risks of food allergy. While absolute proof of safety is not possible, the major risk - transfer of a potent major allergen or nearly identical crossreactive protein - is minimized by allergen-specific serum immunoglobulin E tests that evaluate proteins taken from major allergenic sources or proteins with sequences highly similar to any allergen. Other tests are performed to identify proteins that are likely to sensitize consumers. Experience indicates the current assessment process is working effectively. However, further guidance on bioinformatics and immunoglobulin E assays could increase the reliability of the assessment. Further development of alternative assays may be needed to assess the next generation of products.
转基因植物是通过将外源基因插入植物细胞,然后生成可繁殖的稳定品系植物,从而实现对农业作物的快速、精确改良而产生的。目前的产品提供了对害虫、植物病毒或除草剂的抗性。未来的产品包括营养增强的作物、耐盐和耐旱作物以及植物生产的工业酶或药物。新表达的蛋白质可能引起严重过敏反应的风险是真实存在的,但概率相对较小。监管机构要求对转基因作物进行上市前评估,以降低食物过敏风险增加的可能性。虽然不可能有绝对的安全性证明,但通过过敏原特异性血清免疫球蛋白 E 测试,评估来自主要过敏原来源的蛋白质或与任何过敏原序列高度相似的蛋白质,可以最大限度地减少主要过敏原或几乎相同的交叉反应性蛋白质转移的主要风险。还进行了其他测试以识别可能使消费者致敏的蛋白质。经验表明,目前的评估过程正在有效运作。然而,关于生物信息学和免疫球蛋白 E 检测的进一步指导可以提高评估的可靠性。可能需要进一步开发替代检测方法来评估下一代产品。